Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quercus robur pollen extract
- Development stage
- Phase 2
- Lead developer
- Inmunotek
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Sublingual, Subcutaneous
01
Overview
Quercus robur pollen extract is an allergen immunotherapy product developed by Inmunotek S.L. for the treatment of IgE-mediated allergic diseases caused by English oak pollen. It is indicated for patients suffering from allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma triggered by exposure to English oak (Quercus robur) pollen. The extract is utilized in both subcutaneous (SCIT) and sublingual (SLIT) immunotherapy formulations, such as Alunitek and Oraltek. The mechanism of action involves the induction of peripheral T-cell tolerance, characterized by a shift from a Th2-dominated immune profile to a Th1-dominated profile, the induction of regulatory T cells (Tregs), and the production of allergen-specific IgG4 blocking antibodies. These immunological changes lead to a reduction in mast cell and basophil activation upon subsequent allergen exposure, thereby alleviating clinical symptoms and potentially modifying the natural course of the allergic disease.
- Brand names
- OraltekAlunitekClustek
- Other names
- English oak pollen extractOak pollen extract
02
Targets
A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)sIgG4 (Allergen-specific immunoglobulin G4)
Beyond the preview
Go deeper on quercus robur pollen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quercus robur pollen extract.